A5011789816- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Pancreatic and Hepatic Oncology Research
- T-cell and B-cell Immunology
- Cancer Mechanisms and Therapy
- Gastric Cancer Management and Outcomes
- Immune Cell Function and Interaction
- Immune responses and vaccinations
- Peptidase Inhibition and Analysis
- Inflammatory Biomarkers in Disease Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Cancer, Lipids, and Metabolism
Wuxi People's Hospital
2024
Nanjing Medical University
2024
Army Medical University
2022-2024
Southwest Hospital
2022-2024
Ratio
2024
National Comprehensive Cancer Network
2024
Beijing Drainage Group (China)
2024
Southwest General Health Center
2024
Background & Aims Tumor-associated chronic inflammation has been determined to play a crucial role in tumor progression, angiogenesis and immunosuppression. The objective of this study was assess the prognostic value neutrophil-to-lymphocyte ratio (NLR) platelet-to-lymphocyte (PLR) perihilar cholangiocarcinoma (pCCA) patients following curative resection. Methods Consecutive pCCA resection at 3 Chinese hospitals between 2014 2018 were included. NLR defined as neutrophil count...
Background & aim The association of perioperative blood transfusion (PBT) with long-term survival in perihilar cholangiocarcinoma (pCCA) patients after surgical resection curative intent is controversial and may differ among different stages the disease. This study aimed to investigate impact PBT on pCCA. Methods Consecutive pCCA from three hospitals treated 2012 2019 were enrolled divided into non-PBT groups. Propensity score matching (PSM) was used balance differences baseline...
The prognostic value of carbohydrate antigen 19-9 (CA19-9) is known to be affected by elevated bilirubin levels in patients with gallbladder carcinoma (GBC). clinical significance changes the ratio CA19-9 total (TB) GBC after curative-intent resection remains unknown. aim this study was determine preoperative and postoperative CA19-9/TB these patients.
e16242 Background: Currently, more than 55% of liver cancer patients have recurrence within 1 years after radical surgery. However,there is no standard treatment neoadjuvant therapy for resectable HCC patients. This study aimed to explore the efficacy and safety triple [Tislelizumab combined with lenvatinib plus transcatheter arterial chemoembolization (TACE)] as in high-risk recurrence. Methods: prospective, single-arm, phase II trial (ChiCTR2200059574) enrolled primary who had not received...